vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and ZIONS BANCORPORATION, NATIONAL ASSOCIATION (ZION). Click either name above to swap in a different company.
ZIONS BANCORPORATION, NATIONAL ASSOCIATION is the larger business by last-quarter revenue ($891.0M vs $708.5M, roughly 1.3× Medpace Holdings, Inc.). ZIONS BANCORPORATION, NATIONAL ASSOCIATION runs the higher net margin — 29.5% vs 19.1%, a 10.4% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 8.7%). ZIONS BANCORPORATION, NATIONAL ASSOCIATION produced more free cash flow last quarter ($952.0M vs $188.1M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 9.6%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Zions Bancorporation is an American national bank headquartered in Salt Lake City, Utah. It operates as a national bank rather than as a bank holding company and does business under the following seven brands: Zions Bank, Amegy Bank of Texas, California Bank and Trust, National Bank of Arizona, Nevada State Bank, Vectra Bank Colorado, and the Commerce Bank of Washington.
MEDP vs ZION — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $891.0M |
| Net Profit | $135.1M | $263.0M |
| Gross Margin | — | — |
| Operating Margin | 21.6% | — |
| Net Margin | 19.1% | 29.5% |
| Revenue YoY | 32.0% | 8.7% |
| Net Profit YoY | 15.5% | 21.8% |
| EPS (diluted) | $4.65 | $1.77 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $891.0M | ||
| Q3 25 | $659.9M | $861.0M | ||
| Q2 25 | $603.3M | $838.0M | ||
| Q1 25 | $558.6M | $795.0M | ||
| Q4 24 | $536.6M | $820.0M | ||
| Q3 24 | $533.3M | $792.0M | ||
| Q2 24 | $528.1M | $777.0M | ||
| Q1 24 | $511.0M | $742.0M |
| Q4 25 | $135.1M | $263.0M | ||
| Q3 25 | $111.1M | $222.0M | ||
| Q2 25 | $90.3M | $244.0M | ||
| Q1 25 | $114.6M | $170.0M | ||
| Q4 24 | $117.0M | $216.0M | ||
| Q3 24 | $96.4M | $214.0M | ||
| Q2 24 | $88.4M | $201.0M | ||
| Q1 24 | $102.6M | $153.0M |
| Q4 25 | 21.6% | — | ||
| Q3 25 | 21.5% | — | ||
| Q2 25 | 20.9% | — | ||
| Q1 25 | 20.3% | — | ||
| Q4 24 | 23.4% | — | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | 19.9% | — | ||
| Q1 24 | 20.4% | — |
| Q4 25 | 19.1% | 29.5% | ||
| Q3 25 | 16.8% | 25.8% | ||
| Q2 25 | 15.0% | 29.1% | ||
| Q1 25 | 20.5% | 21.4% | ||
| Q4 24 | 21.8% | 26.3% | ||
| Q3 24 | 18.1% | 27.0% | ||
| Q2 24 | 16.7% | 25.9% | ||
| Q1 24 | 20.1% | 20.6% |
| Q4 25 | $4.65 | $1.77 | ||
| Q3 25 | $3.86 | $1.48 | ||
| Q2 25 | $3.10 | $1.63 | ||
| Q1 25 | $3.67 | $1.13 | ||
| Q4 24 | $3.67 | $1.34 | ||
| Q3 24 | $3.01 | $1.37 | ||
| Q2 24 | $2.75 | $1.28 | ||
| Q1 24 | $3.20 | $0.96 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | — |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $459.1M | $7.2B |
| Total Assets | $2.0B | $89.0B |
| Debt / EquityLower = less leverage | — | 0.21× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | — | ||
| Q3 25 | $285.4M | — | ||
| Q2 25 | $46.3M | — | ||
| Q1 25 | $441.4M | — | ||
| Q4 24 | $669.4M | — | ||
| Q3 24 | $656.9M | — | ||
| Q2 24 | $510.9M | — | ||
| Q1 24 | $407.0M | — |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $970.0M | ||
| Q1 25 | — | $964.0M | ||
| Q4 24 | — | $950.0M | ||
| Q3 24 | — | $548.0M | ||
| Q2 24 | — | $546.0M | ||
| Q1 24 | — | $544.0M |
| Q4 25 | $459.1M | $7.2B | ||
| Q3 25 | $293.6M | $6.9B | ||
| Q2 25 | $172.4M | $6.6B | ||
| Q1 25 | $593.6M | $6.3B | ||
| Q4 24 | $825.5M | $6.1B | ||
| Q3 24 | $881.4M | $6.4B | ||
| Q2 24 | $763.6M | $6.0B | ||
| Q1 24 | $671.5M | $5.8B |
| Q4 25 | $2.0B | $89.0B | ||
| Q3 25 | $1.8B | $88.5B | ||
| Q2 25 | $1.6B | $88.9B | ||
| Q1 25 | $1.9B | $88.0B | ||
| Q4 24 | $2.1B | $88.8B | ||
| Q3 24 | $2.1B | $87.0B | ||
| Q2 24 | $1.9B | $87.6B | ||
| Q1 24 | $1.8B | $87.1B |
| Q4 25 | — | 0.21× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.15× | ||
| Q4 24 | — | 0.16× | ||
| Q3 24 | — | 0.09× | ||
| Q2 24 | — | 0.09× | ||
| Q1 24 | — | 0.09× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $1.1B |
| Free Cash FlowOCF − Capex | $188.1M | $952.0M |
| FCF MarginFCF / Revenue | 26.6% | 106.8% |
| Capex IntensityCapex / Revenue | 0.6% | 13.6% |
| Cash ConversionOCF / Net Profit | 1.43× | 4.08× |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $1.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $1.1B | ||
| Q3 25 | $246.2M | $438.0M | ||
| Q2 25 | $148.5M | $-62.0M | ||
| Q1 25 | $125.8M | $179.0M | ||
| Q4 24 | $190.7M | $1.1B | ||
| Q3 24 | $149.1M | $119.0M | ||
| Q2 24 | $116.4M | $251.0M | ||
| Q1 24 | $152.7M | $261.0M |
| Q4 25 | $188.1M | $952.0M | ||
| Q3 25 | $235.5M | $413.0M | ||
| Q2 25 | $142.4M | $-93.0M | ||
| Q1 25 | $115.8M | $152.0M | ||
| Q4 24 | $183.0M | $1.1B | ||
| Q3 24 | $138.5M | $97.0M | ||
| Q2 24 | $103.5M | $234.0M | ||
| Q1 24 | $147.2M | $231.0M |
| Q4 25 | 26.6% | 106.8% | ||
| Q3 25 | 35.7% | 48.0% | ||
| Q2 25 | 23.6% | -11.1% | ||
| Q1 25 | 20.7% | 19.1% | ||
| Q4 24 | 34.1% | 128.2% | ||
| Q3 24 | 26.0% | 12.2% | ||
| Q2 24 | 19.6% | 30.1% | ||
| Q1 24 | 28.8% | 31.1% |
| Q4 25 | 0.6% | 13.6% | ||
| Q3 25 | 1.6% | 2.9% | ||
| Q2 25 | 1.0% | 3.7% | ||
| Q1 25 | 1.8% | 3.4% | ||
| Q4 24 | 1.4% | 11.8% | ||
| Q3 24 | 2.0% | 2.8% | ||
| Q2 24 | 2.4% | 2.2% | ||
| Q1 24 | 1.1% | 4.0% |
| Q4 25 | 1.43× | 4.08× | ||
| Q3 25 | 2.22× | 1.97× | ||
| Q2 25 | 1.65× | -0.25× | ||
| Q1 25 | 1.10× | 1.05× | ||
| Q4 24 | 1.63× | 5.31× | ||
| Q3 24 | 1.55× | 0.56× | ||
| Q2 24 | 1.32× | 1.25× | ||
| Q1 24 | 1.49× | 1.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
ZION
Segment breakdown not available.
